NEWS

Source: Startup Health
SynchNeuro has secured seed-stage support from Boomerang Ventures to advance its brain-based, non-invasive continuous glucose monitoring technology. Using EEG-derived signals decoded by machine learning, the company is developing a wearable “Cardiometabolic Advisor” that tracks blood glucose and metabolic indicators without needles. The investment accelerates development and moves the device closer to broad market adoption.